
Lipigon Pharmaceuticals Investor Relations Material
Latest events

Q1 2025
22 May, 2025

Q4 2024
28 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Lipigon Pharmaceuticals
Access all reports
Lipigon Pharmaceuticals AB specializes in developing therapeutics for lipid-related disorders. The company focuses on creating drugs with unique mechanisms of action to treat diseases resulting from disruptions in the body's lipid metabolism. Their projects include treatments for severe hypertriglyceridemia, familial chylomicronemia syndrome, lipodystrophy, dyslipidemia, and acute respiratory distress syndrome. The company is headquartered in Umeå, Sweden, and its shares are listed on the OMX Stockholm.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
LPGO
Country
🇸🇪 Sweden